Figure 3.

The effect of calcium channel blocker and extracellular calcium removal on FDA-induced uterine contraction. Representative image of isometric uterine contraction following administration of (a) 2 mg/ml FDA plus oxodipine, (b) oxytocin plus oxodipine, (c) 2 mg/ml FDA plus EDTA and (d) oxytocin plus EDTA while bar chart shows the Emax following oxodipine and EDTA administration as compared to the control. Contraction was almost abolished following EDTA administration in the isolated uteri pre-exposed to FDA. n = 6 (* p < 0.05).